GlassScriptPhysician profile
Eugene A Preston
NPI 1134225550
$3,479.65
in general payments reported to CMS, 2019-2025
26 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $1,081 · 2023: $866 · 2024: $666 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $632.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $383.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $331.61 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $329.77 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Merck Sharp & Dohme LLC | $241.44 | 2021-2024 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $235.22 | 2022-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.47 | 2021-2025 | Jardiance, Ofev, Synjardy |
| Astellas Pharma US INC | $167.53 | 2021-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $148.05 | 2021-2025 | Injectafer |
| Pfizer INC. | $105.38 | 2022-2024 | |
| Abbott Laboratories | $99.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.60 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $63.65 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.54 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.32 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.50 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $50.86 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $46.01 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $38.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.10 | 2022 | |
| Axsome Therapeutics, INC. | $25.76 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $25.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2022 | |
| Amgen INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.